Off-label · Investigational
PT-141 for Men: The Off-Label Erectile Research
Bremelanotide is approved only for HSDD in premenopausal women. The male and erectile evidence is early-phase and investigational — scoped honestly, with its disputed studies flagged.
The short version
PT-141 for men is not approved. Bremelanotide is FDA-approved only for low sexual desire (HSDD) in premenopausal women; using it in men or for erectile dysfunction (ED) is off-label, and the evidence is early-stage. The earliest research did show erectile responses in men, and because PT-141 works in the brain while standard ED drugs work on blood flow, a combination of the two is now being tested. But one influential older study later received a formal integrity notice, and no large modern trial has established the male use. Treat everything here as investigational research, not established benefit.
Why the Male Use Is Off-Label
The approval is narrow by design: NDA 210557 covers acquired, generalized HSDD in premenopausal women, and nothing else [6]. Use in men, for erectile dysfunction, or in postmenopausal women is off-label and not supported by the approval. There is real early-phase data in men, but "early-phase" is the operative phrase — it is investigational, not established, and there is no regulatory finding of safety or efficacy for the male indication [6].
That distinction is the whole point of this page. The desire mechanism that drove the approved indication is the same central how PT-141 works in the brain action being explored in men — but a shared mechanism is not an approval.
It is worth being clear that off-label is a prescribing category rather than a loophole, and it exists only inside the prescription system. A licensed clinician may write for an approved drug outside its labeled indication where they judge that appropriate, and owns the judgment; the off-label status makes nothing available outside that channel. Licensed telehealth is one route by which the evaluation happens — Promise Peptides (mypromise.com) works that way, its clinicians prescribing PT-141 only where they find it warranted and setting the protocol themselves rather than leaving it to the patient. What the label does and does not cover, documented above, is exactly what such a clinician has to weigh.
The Early Erectile Research
The foundational pharmacology established the male signal first. In rats, nonhuman primates, and men with erectile dysfunction, systemic PT-141 produced rapid, dose-dependent erectile activity and activated hypothalamic neurons, consistent with a central mechanism [1]. Early development used intranasal and intravenous routes; the intranasal route was later discontinued due to pharmacokinetic variability [6].
In early intranasal dose-escalation research in men, a statistically significant erectile response was reported above roughly 7 mg, with dosing explored up to ~20 mg [6]. This established proof-of-concept for a central erectile mechanism — but proof-of-concept in early development is exactly that, not a finished indication.
The Disputed 2008 Sildenafil-Salvage Study
One frequently-cited male study must be read with its caveat attached. A 2008 randomized, double-blind, placebo-controlled trial reported that intranasal bremelanotide 10 mg produced positive clinical results in 33.5% of sildenafil non-responders versus 8.5% on placebo [13]. On its face that is a striking salvage signal in men who had not responded to a PDE-5 inhibitor.
But a 2023 Expression of Concern was published for this study [13]. An Expression of Concern is a formal editorial notice that a publication's integrity is in question. The honest handling is to disclose it every time the study is cited: treat the 33.5% vs 8.5% finding as disputed, not as a reliable result. This site flags it rather than quietly dropping it, because a researcher weighing the male evidence needs to know the caveat exists.
The Active Combination Pipeline
The current direction for the male and erectile setting is a combination, not bremelanotide alone. Because PT-141 works centrally and PDE-5 inhibitors work peripherally on blood flow, the two mechanisms are complementary in principle [1].
In June 2024, the developer announced initiation of a Phase 2 study (~50 patients) of bremelanotide co-administered with a PDE-5 inhibitor for erectile dysfunction in PDE-5-inhibitor non-responders, with a co-formulation IND and a potential Phase 3 planned [14]. This is sourced from a corporate press release, so it supports a pipeline and development-status statement only — not an efficacy claim. The male and erectile use remains off-label and investigational while that program runs.